macrolides: pharmacokinetics and pharmacodynamics · macrolides: pharmacokinetics and...
TRANSCRIPT
![Page 1: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/1.jpg)
MACROLIDES: pharmacokinetics and pharmacodynamics
P. M. Tulkens, MD, PhD
Unité de Pharmacologie Cellulaire et MoléculaireUniversité Catholique de Louvain, Brussels, Belgium
International Society of Anti-infective Pharmacology
www.md.ucl.ac.be/facm www.isap.org
![Page 2: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/2.jpg)
Pharmacokinetics / pharmacodynamicsas a step towards therapy...
patient’scure
theideal
molecule
chemistry therapyPK/PD
the big
black box
microbiology
brilliant and
clear solutions
![Page 3: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/3.jpg)
PK/PD parameters: a first sight
• Peak• Trough• Area under the curve
SerumConcentrationvarying with time
![Page 4: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/4.jpg)
What does the clinician(and the patient) want ?
DosageSerum
Concentrationvarying over time
therapeuticeffects
toxic effects
freely adapted from W.A. Craig
Max
min
![Page 5: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/5.jpg)
Pharmacokinetics ...
DosageSerum
Concentrationvarying over time
Concentrationat the site of
infection
Concentration innon-target tissues
therapeuticeffects
toxic effects
adapted from W.A. Craig
Max
min
![Page 6: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/6.jpg)
Pharmacodynamics ...
DosageSerum
Concentrationvarying over time
Concentrationat the site of
infection
Concentration innon-target tissues
therapeuticeffects
toxic effects
adapted from W.A. Craig
Max
min
![Page 7: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/7.jpg)
Pharmacokinetic/ Pharmacodynamics in DrugDevelopment and Evaluation of Efficacy (1/2)
The combination of
• in vitro modelling, • proper design of animal model experiments, • pharmacokinetic information on patients in clinical trials
allows an in depth understanding of which aspects of drug exposure are most closely linked to • therapeutic outcomes (successes as well as failures !!)• quantifiable / predictable toxicity hazards
![Page 8: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/8.jpg)
PK/PDin drug
develop-ment
A viewfromFDA
http://www.fda.gov/cder/present/anti-infective798/biopharm/index.htm
![Page 9: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/9.jpg)
Pharmacokinetic/ Pharmacodynamics in DrugDevelopment and Evaluation of Efficacy (2/2)
By providing such information to clinicians, drug therapy can achieve the goal of maximal therapeutic effect while engendering the lowest probability of encountering a drug exposure-related adverse event.
ISAP / FDA workshop, March 1st, 1999
http://www.isap.org/Rockville-1999.htm
![Page 10: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/10.jpg)
Pharmacokinetic/ Pharmacodynamics andantibiotic resistance...
Inadequate dosing of antibiotics is probably an important reason formisuse and subsequent risk of resistance.
A recommendation on proper dosing regimens for differentinfections would be an important part of a comprehensive strategy.
The possibility to produce such a dose recommendation based onpharmacokinetic and pharmacodynamic considerations will befurther investigated in one of the CPMP working parties…
EMEA discussion paper on Antimicrobial resistance,January 3, 1999EMEA/9880/99
![Page 11: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/11.jpg)
PK/PDanddrug
devlop-ment
A viewfrom
EMEA
http://www.eudra.org/humandocs/PDFs/EWP/265599en.pdfhttp://www.isap.org/1999/Uppsala/intro.htm
open for comments until March 2000open for comments until March 2000
![Page 12: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/12.jpg)
Pharmacokinetic/ Pharmacodynamics in DrugDevelopment and Evaluation
Who should take these points in consideration ?
1. Industry: surely ! (for sake of efficacy both short and long term) but what do they do with that ?
2. Clinicians: more and more (to optimize therapy) but they often feel alone or insufficiently informed
3. Regulatory bodies (to better appraise new drugs) but they wish to be certain that this is the correct way !
![Page 13: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/13.jpg)
Pharmacokinetic / Pharmacodynamicparameters: a 2d sight
Peak / troughAUC / Time
Minimal inhibitoryconcentration>
![Page 14: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/14.jpg)
PK/PD: role of concentration
Marked effect Weak effect important concentration little or no concentration
dependency dependency
aminoglycosides ββββ-lactams (all) fluoroquinolones glycopeptides metronidazole macrolides
daptomycin clindamycineketolides tétracyclinesamphotericin
Optimize the concentration
![Page 15: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/15.jpg)
PK/PD: role ofconcentration
an example withListeria
monocytogenes
multiples of MIC
bact
eria
l kill
ing
(log
redu
ctio
n)
sparfloxacin
azithromycin
ampicillinOuadrhiri et al., Antimicrob. AgentsChemother., 1999
![Page 16: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/16.jpg)
PK/PD: role of time
Kill quickly Kill more slowly
aminoglycosides ββββ-lactams (all) fluoroquinolones glycopeptides
macrolidesoxazolidinonesclindamycinetetracyclinesflucytosine
Optimize the time
![Page 17: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/17.jpg)
PK/PD: prolonged effects
• Post antibiotic effect (PAE)delay in regrowth upon antibiotic removal
• Sub-MIC activity (SME)tests the distribution of antibiotic susceptibility in the bacterial population
• Post antibiotic leucocyte enhanced effect (PLAE)pre-treatment makes bacteria more susceptible to phagocytosis and killing
![Page 18: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/18.jpg)
PK/PD: role of prolonged effects
Marked influence Weak of no influence
aminoglycosides ββββ-lactams (all) fluoroquinolones macrolides
azithromycin clindamycineglycopeptidestertracyclinesstreptograminsfluconazole
Optimize the amount of drug
![Page 19: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/19.jpg)
• Cyclophosphamide 150 and 100 mg/kg at 4 and 1day before infection
• Thigh infection produced by injection of 0.1 ml of 107
CFU/ml 2 hrs before treatment
• Lung infection produced by 45 min aerosol of 109
CFU/ml 14 hrs before treatment
• 107-8 CFU/g in thigh or lung at start of therapy
Neutropenic Murine Thigh andLung Infection Models
W.A. Craig et al.
![Page 20: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/20.jpg)
PK/PD Parameters Correlating with Efficacy inMurine Thigh and Lung Infections
Time Above MIC AUC (Peak)Penicillins AminoglycosidesCephalosporins FluoroquinolonesCarbapenems MetronidazoleMonobactams DaptomycinTribactams KetolidesMacrolides AzithromycinClindamycin StreptograminsOxazolidinones GlycopeptidesGlycylcyclines Tetracyclines
W.A. Craig et al.
![Page 21: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/21.jpg)
the 24h-AUC is theintegral of the serum
concentration over the 24hinterval…
proport. to the totaldaily dose and thebioavailability
How do you get a given 24h-AUC ?1. importance of the dose (a)
adjust the total daily dose by ...Thus...
![Page 22: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/22.jpg)
the 24h-AUC is theintegral of the serum
concentration over the 24hinterval…
proport. to the totaldaily dose and thebioavailability
How do you get a given 24h-AUC ?1. administer the right dose...
adjust the total daily dose by ...Thus...
performing singledose increases ...
600 mg
200 mg
![Page 23: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/23.jpg)
the 24h-AUC is theintegral of the serum
concentration over the 24hinterval…
proport. to the totaldaily dose and thebioavailability
How do you get a given 24h-AUC ?2. give a dose frequently
adjust the total daily dose ...Thus...
or, by repeatingsingle doses over
24h
![Page 24: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/24.jpg)
the 24h-AUC is
inversely proport.to the clearance
Use a drug witha long half-life
Thus...
24h-AUC =
(24h-Dose x Bav) / Cl
t1/2 = 6 h t1/2 = 2 h
How do you get a given 24h-AUC ?3. get a low clearance
![Page 25: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/25.jpg)
But isn’t anything more ?
A bacteria wich does not get killed is acollection of genes that can mutate !!
![Page 26: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/26.jpg)
How to predict efficacy in the intracellularmilieu ?
LegionellaChlamydia, ...
S. aureusSalmonella,M. leprae, ...
Listeria hly+,Shigella
phagosomesphagolysosomes
cytosol endosomes
Where are bacteria ?
![Page 27: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/27.jpg)
Pharmacokinetic modulationof intracellular activity: drug trapping
N
S
COO
CH3O
CH3
HNC
O
-
O
H3C
OH
OH
OH
CH3
H3CH2C O
O
CH3
CH3
H3C
O
O
OHO
(H3C)2NHCH3
OH
NHCH3
CH3
H3C
H3C
H3CO
+
+
3
N
COO
O
F -
NN
NH2
F
H3C
H C
2H +
PENI AZ0
25
50
75
100
SP
cellular accumulation:
+
A-
B+
A-
B+B+
![Page 28: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/28.jpg)
How to predict efficacy in the intracellular milieu ?Both serum and cellular concentration fluctuate !
(Azithromycin; 500 mg qd)
serum cell
Intra-cellular
min.concentr.
> 6 !Serum min.
concentr.∼∼∼∼ 0.05
Van Bambeke et al, JAC, 1998, 42:761-767
![Page 29: MACROLIDES: pharmacokinetics and pharmacodynamics · MACROLIDES: pharmacokinetics and pharmacodynamics P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université](https://reader030.vdocument.in/reader030/viewer/2022013014/5ae110f57f8b9a97518e071b/html5/thumbnails/29.jpg)
And we may have a very bright future...
www.md.ucl.ac.be/facm
F. Van BambekeY. OuadrhiriS. CarrynH. ChanteuxH. Servais
W.A. CraigG.L. DrusanoJ.J. SchentagA. McGowan...
http://www.isap.org